- Home
- PBFS vs TNGX Comparison
PBFS vs TNGX Comparison
Compare PBFS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- TNGX
- Stock Information
- Founded
- PBFS 1889
- TNGX 2014
- Country
- PBFS United States
- TNGX United States
- Employees
- PBFS N/A
- TNGX N/A
- Industry
- PBFS Banks
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- TNGX Health Care
- Exchange
- PBFS Nasdaq
- TNGX Nasdaq
- Market Cap
- PBFS 311.6M
- TNGX 723.2M
- IPO Year
- PBFS N/A
- TNGX N/A
- Fundamental
- Price
- PBFS $13.35
- TNGX $6.53
- Analyst Decision
- PBFS
- TNGX Strong Buy
- Analyst Count
- PBFS 0
- TNGX 6
- Target Price
- PBFS N/A
- TNGX $10.00
- AVG Volume (30 Days)
- PBFS 21.4K
- TNGX 1.4M
- Earning Date
- PBFS 11-11-2025
- TNGX 11-05-2025
- Dividend Yield
- PBFS N/A
- TNGX N/A
- EPS Growth
- PBFS 50.26
- TNGX N/A
- EPS
- PBFS 0.91
- TNGX N/A
- Revenue
- PBFS $91,369,000.00
- TNGX $24,296,000.00
- Revenue This Year
- PBFS N/A
- TNGX $6.56
- Revenue Next Year
- PBFS N/A
- TNGX N/A
- P/E Ratio
- PBFS $14.67
- TNGX N/A
- Revenue Growth
- PBFS 23.15
- TNGX N/A
- 52 Week Low
- PBFS $10.60
- TNGX $1.03
- 52 Week High
- PBFS $13.44
- TNGX $10.85
- Technical
- Relative Strength Index (RSI)
- PBFS 63.09
- TNGX 47.47
- Support Level
- PBFS $13.14
- TNGX $6.25
- Resistance Level
- PBFS $13.26
- TNGX $7.40
- Average True Range (ATR)
- PBFS 0.22
- TNGX 0.40
- MACD
- PBFS 0.02
- TNGX -0.06
- Stochastic Oscillator
- PBFS 87.32
- TNGX 24.35
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.